Psoriasis - Pipeline Review, H2 2015

Psoriasis - Pipeline Review, H2 2015

Code: GMDHC7198IDB | Published: Dec-2015 | Pages: 750 | Global Markets Direct
Price :

* Required Fields



Psoriasis - Pipeline Review, H2 2015


Global Markets Directs, Psoriasis - Pipeline Review, H2 2015, provides an overview of the Psoriasiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

3SBio Inc.
Abeome Corporation
AbGenomics International, Inc.
ADC Therapeutics Sarl
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Ajinomoto Pharmaceuticals Co., Ltd.
Allozyne, Inc.
Almirall, S.A.
Amgen Inc.
Anacor Pharmaceuticals, Inc.
AnaptysBio, Inc.
Arena Pharmaceuticals, Inc.
Argos Therapeutics, Inc.
Arrien Pharmaceuticals, LLC
AstraZeneca Plc
Athenex, Inc.
Aurigene Discovery Technologies Limited
Avesthagen Limited
Avexxin AS
Basilea Pharmaceutica AG
Biocon Limited
BioLingus AG
BioMAS Ltd.
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Brickell Biotech, Inc.
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Celgene Corporation
Cellceutix Corporation
Celltrion, Inc.
ChemoCentryx, Inc.
Chipscreen Biosciences Ltd
ChironWells GmbH
Coherus BioSciences, Inc.
Compugen Ltd.
Convoy Therapeutics, Inc.
Creabilis SA
Crescendo Biologics Limited
Delenex Therapeutics AG
Deltanoid Pharmaceuticals Inc.
Dermira Inc.
Domainex Limited
Dr. August Wolff GmbH & Co. KG Arzneimittle
Effimune SAS
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exicure, Inc.
Foamix Pharmaceuticals Ltd.
Forward Pharma A/S
Galectin Therapeutics, Inc.
Gem Pharmaceuticals, LLC
Gene Signal International SA
Genentech, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
GliaCure Inc.
GlycoMar Limited
Grupo Ferrer Internacional, S.A.
Hydra Biosciences, Inc.
Idera Pharmaceuticals, Inc.
Immune Pharmaceuticals Inc.
Immune Response BioPharma, Inc.
Innovent Biologics, Inc.
Invion Limited
Jenrin Discovery, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
KaloBios Pharmaceuticals, Inc.
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lead Pharma Holding B.V.
Lees Pharmaceutical Holdings Limited
LEO Pharma A/S
Lipidor AB
Lupin Limited
Mabion SA
Mabtech Limited
mAbxience S.A.
Maruho Co., Ltd.
MediGene AG
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Neovacs SA
Nimbus Therapeutics, LLC
NovaLead Pharma Pvt. Ltd.
Novartis AG
Nuevolution A/S
Nuvo Research Inc.
Oncobiologics, Inc.
OPKO Health, Inc.
Panacea Biotec Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Phenex Pharmaceuticals AG
PinCell srl
Polichem S.A.
Promius Pharma, LLC
Protalix BioTherapeutics, Inc.
Prothena Corporation Plc
Provectus Biopharmaceuticals, Inc.
RedHill Biopharma Ltd.
Rigel Pharmaceuticals, Inc.
Salix Pharmaceuticals Ltd.
Sandoz International GmbH
Sareum Holdings Plc
Selvita SA
Shulov Innovative Science Ltd.
Sigmoid Pharma Limited
SignPath Pharma Inc
Soligenix, Inc.
Spherium Biomed S.L.
sterna biologicals Gmbh & Co KG
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
Telormedix SA
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Limited
Therapeutic Proteins International, LLC
Therapix Biosciences Ltd
Tolero Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Vitae Pharmaceuticals, Inc.
vTv Therapeutics LLC
Welichem Biotech Inc.
Wellstat Therapeutics Corporation
Yuhan Corporation
Ziarco Pharma Ltd

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients